Partnering with
MOGRIFY
Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical. We are particularly interested in speaking with those with interest in immuno-oncology, ophthalmology as well as other disease areas where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development and co-development partnerships, as well as the exploration and generation of novel cell-based and in vivo reprogramming therapies for broad therapeutic application.
Current
PARTNERS
Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering.
MRC Laboratory for Molecular Biology
The MRC Laboratory of Molecular Biology (LMB) is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. In doing so, they provide knowledge needed to solve key problems in human health.
Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology
Duke-NUS Medical School
Duke-NUS Medical School is a research powerhouse and our distinguished scientists are transforming the way we understand, diagnose and treat diseases. Our founder, Assistant Professor, Owen Rackham, and his group at the School focus on what defines human cells and how their phenotype emerges from the complex interplay between the genome, transcriptome and environment. Developing methods that leverage the large volume of gene expression, epigenetic and interaction data that is being generated to develop biological hypotheses about how certain perturbations can influence cell fate.
Monash University
The Polo Laboratory, a part of the Monash Biomedicine Discovery Institute at Monash University, focuses on the transcriptional and epigenetic mechanisms that govern cell identity, in particular, pluripotency and the reprogramming of somatic cells into induced pluripotent stem (iPS) cells.
Our
PIPELINE
| AREA | Sample Acquisition | Bioinformatics | In vitro PoC | In vivo PoC | IND | Clinical | Marketing |
|---|---|---|---|---|---|---|---|
| Immunotherapy (Oncology) | mogrify | mogrify | mogrify | mogrify | partner | partner | |
| Ophthalmology (Retinal) | mogrify | mogrify | mogrify | partner | partner | ||
| Collaborations (Pulmonary, Metabolic & Others) | mogrify | mogrify | mogrify | partner | partner | partner | partner |
| mogrify | Mogrify Progress | partner | Expect to Partner |
Upcoming
Events & Conferences
Advanced Therapies Integrates is dedicated to bringing together the industry leaders to help drive and deliver the full potential advanced therapies and medicinal products (ATMPs).
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
The LSCN will be hosting its 4th annual symposium in collaboration with The Francis Crick Institute. The event will feature keynote speakers Prof Hans Clevers (Hubrecht Institute, The Netherlands) and Prof. Dominique Bonnet, as well as invited speakers and short talks and posters.
The international BIO-Europe® 2021 gathering will be held digitally on October 25-28, bringing together global biopharma and investment leaders to build partnerships that facilitate innovation and medical breakthroughs.
The 2021 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.
LSX’s Investival Showcase connects life science corporates to global capital and partners in an international showcase of early, growth stage and public life science and health technology companies across Europe and beyond.
The 4th Annual Ophthalmic Drugs Conference taking place in person on the 22nd-23rd of November 2021, in London.
The British Society for Immunology Congress 2021, the annual flagship event, will take place from 28 November to 1 December 2021 in Edinburgh, UK.
The American Society of Hematology (ASH) Annual Meeting & Exposition is the annual premier event in malignant and non-malignant hematology.